← SynDRA
DANTROLENE
SynDRA canonical compound SYN0023516 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | RYR1 | RYR3 |
|---|
| Mechanism of action | calcium channel blocker |
|---|
| Indication | malignant hyperthermia (MH) | spasms |
|---|
| Disease area | endocrinology | neurology/psychiatry |
|---|
All known targets
Mechanisms of action (all sources)
- RYR1 ANTAGONIST
- Ryanodine receptor 1 antagonist
- RYR3 ANTAGONIST
- Ryanodine receptor 3 antagonist
- calcium channel blocker
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- ATXN2
- BLM
- GMNN
- MAPT
- MBNL1
- PMP22
- SLCO1B1
- SLCO1B3
- SMN1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AHR
- ANDR
- ESR1
- ESRRA
- GLI3
- HCRTR1
- IFNG
- SC5A7
Drug classes
- Central Nervous System Agents
- Muscle Relaxants, Central
- Neuromuscular Agents
- Peripheral Nervous System Agents
- Skeletal Muscle Relaxant
ATC classes
- MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS
Cross-references
Synonyms
- DANTRIUM
- DANTROLENE SODIUM
- Dantrium
- REVONTO
- RYANODEX
- Revonto
- Ryanodex
- dantrolene sodium
- dantrium
- dantrolene sodium salt
- Dantroleno
- 2-methylbenzoic acid anilide
- Bebenil
- Mebenil
- O-methylbenzanilide
- O-toluanilide
- BAS-305
- BAS-3050
- BAS-3050F
- F-368
- NSC-227402
- NSC-26404
- SHA-458100
- Dantrolenum
- Dantrium Intravenous
- Dantrium (TN)
- Dantrolen (TN)
- Dantroleno [INN-Spanish]
- Dantrolenum [INN-Latin]
- Dantrolene (USAN/INN)
- Dantrolene [USAN:BAN:INN]
- 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin
- dantrolene (usp-rs)
- F64QU97QCR
- 1-[[5-(p-Nitrophenyl)furfurylidene]amino]hydantoin
- CHEBI:4317
- RefChem:57723
- DTXCID602881
Reported adverse events
- Hypersensitivity
- Chills
- Pleural effusion
- Tachycardia
- Constipation
- Hepatitis
- Myalgia
- Injection site reaction
- Headache
- Nausea
- Vomiting
- Asthenia
Look up DANTROLENE in the interactive SynDRA portal →